Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced that a study completed at National ...
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced ...
Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) announced today that it has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in ...
delivery for treatment after exposure. AEOL 10150 has been shown to be safe and well tolerated in two phase 1 safety studies, and in animal studies it has been proven to be efficacious in protecting ...
MISSION VIEJO, CA--(Marketwired - Oct 29, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Optimal dose of AEOL 10150 improved survival by four times over untreated animals Treatment with AEOL 10150 ...
Aeolus Pharmaceuticals Inc., a biotechnology company leveraging significant government funding to develop a platform of novel compounds in oncology and biodefense, has reported additional results from ...
Aeolus Pharmaceuticals, Inc. announced the publication of data on AEOL 11207 in epilepsy in Neurobiology of Disease. The article, titled "Mitochondrial oxidative stress and epilepsy in SOD2 deficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results